Benzo[b][1,8]napthyridin-2(1H)-one | 112499-49-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Benzo[b][1,8]napthyridin-2(1H)-one
• 英文别名: 1H-benzo[b][1,8]naphthyridin-2-one
• CAS: 112499-49-7
• 化学式: C₁₂H₈N₂O
• 分子量: 196.2
• InChiKey: MMQLBTDCVNCJBE-UHFFFAOYSA-N

物化性质

• 熔点：
  221-222 °C(Solv: methanol (67-56-1))
• 沸点：
  382.0±52.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Benzo[b][1,8]napthyridin-2(1H)-one 、 碘甲烷 、 N,N-二甲基甲酰胺 以47%的产率得到
  参考文献：
  名称：

  REISCH, JOHANNES;SCHEER, MATHIAS, ARCH. PHARM., 320,(1987) N 11, 1174-1180

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基苯甲醛 、 2,6-二羟基吡啶 以41%的产率得到
  参考文献：
  名称：

  REISCH, JOHANNES;SCHEER, MATHIAS, ARCH. PHARM., 320,(1987) N 11, 1174-1180

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS<br/>[FR] COMPOSÉS ET COMPOSITIONS SERVANT DE MODULATEURS DE L'ACTIVITÉ DES TLR
  申请人：IRM LLC

  公开号：WO2009111337A1

  公开（公告）日：2009-09-11

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is -CR4=CR5.

  该发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物来治疗或预防与Toll样受体相关的疾病或紊乱的方法，包括TLR7和TLR8。在一个方面，这些化合物可用作辅助剂，以增强疫苗的效果（公式I），其中：X3为N；X4为N或CR3；X5为-CR4=CR5。
• METAL CHELATING COMPOSITIONS AND METHODS FOR CONTROLLING THE GROWTH OR ACTIVITIES OF A LIVING CELL OR ORGANISM
  申请人：HOLBEIN Bruce Edward

  公开号：US20160038604A1

  公开（公告）日：2016-02-11

  The present invention provides for metal chelating compositions which are soluble in aqueous media. The present invention also provides chelating compositions that possess acceptable iron sequestering strengths and are able to present a physical form that potentially inhibits (e.g. does not permit easy) access of iron sequestered by the compositions to the cells being targeted. Compositions comprising chelating aspects affixed to or incorporated into suitable carrier materials such that the resulting metal chelating composition is soluble in aqueous media are also provided. Disclosed herein are chelating compositions, for chelating one or more essential metals. The chelating compositions being soluble in an aqueous medium and comprising one or more metal binding chemical groups affixed to or incorporated into the structure of a carrier material, such that the resulting chelating composition is able to bind one or more metals, and remains substantially soluble in the aqueous medium with its bound metal or metals.

  本发明提供了在水性介质中可溶的金属螯合组合物。本发明还提供了具有可接受的铁螯合强度并能呈现一种物理形式的螯合组合物，该物理形式可能抑制（例如，不允许易于）被组合物螯合的铁进入目标细胞。还提供了包含螯合方面固定在或并入适当载体材料中的组合物，从而使得所得的金属螯合组合物在水性介质中可溶。本文公开了用于螯合一个或多个必需金属的螯合组合物。这些螯合组合物在水性介质中可溶，包括一个或多个金属结合化学基固定在或并入载体材料的结构中，使得所得的螯合组合物能够结合一个或多个金属，并且在水性介质中与其结合的金属或金属保持基本可溶解。
• TRICYCLIC KINASE INHIBITORS OF MELK ANDS METHODS OF USE
  申请人：Dana-Farber Cancer Institute, Inc

  公开号：US20190084977A1

  公开（公告）日：2019-03-21

  Provided herein are tricyclic small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK). The compounds are useful for treating cancer and other conditions or diseases associated with aberrant MELK expression. Also provided herein are pharmaceutical compositions comprising a tricyclic compound of the invention and a pharmaceutically acceptable carrier. The invention also provides methods of treating cancers associated with over-expression of MELK.

  本文提供了三环小分子抑制剂母源胚胎亮氨酸拉链激酶（MELK）。这些化合物可用于治疗与异常MELK表达相关的癌症和其他疾病或症状。本文还提供了包含本发明的三环化合物和药用可接受载体的药物组合物。本发明还提供了治疗与MELK过表达相关的癌症的方法。
• [EN] METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA<br/>[FR] PROCÉDÉ POUR TRAITER UN LYMPHOME LYMPHOPLASMOCYTAIRE
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2015089479A1

  公开（公告）日：2015-06-18

  The present invention provides compounds of any one of Formulae (A), (I-11), (II), and (V) (e.g., compounds of Formula (A-1)-(A-18)), and methods for treating Waldenström's macroglobulinemia (WM) and other B cell neoplams in a subject using the compounds. The methods comprise administering to a subject in need thereof an effective amount of the compounds. Also provided are methods to treat B cell neoplasms using the compounds in combination with inhibitors of Bruton's tyrosine kinase (BTK), interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), bone marrow on X chromosome kinase (BMX), phosphoinositide 3-kinase (PI3K), transforming growth factor b-activated kinase-1 (TAK1), and/or a Src family kinase.

  本发明提供了任一式(A)、(I-11)、(II)和(V)的化合物（例如，式(A-1)-(A-18)的化合物），以及使用这些化合物治疗瓦尔登斯特朗巨球蛋白血症（WM）和其他B细胞肿瘤的方法。该方法包括向需要该化合物的受试者施用有效量的化合物。此外，还提供了使用该化合物与布鲁顿酪氨酸激酶（BTK）抑制剂、白细胞介素-1受体相关激酶1（IRAK1）、白细胞介素-1受体相关激酶4（IRAK4）、骨髓X染色体激酶（BMX）、磷脂酰肌醇3-激酶（PI3K）、转化生长因子b激活的激酶-1（TAK1）和/或Src家族激酶联合治疗B细胞肿瘤的方法。
• [EN] A PROCESS FOR THE PREPARATION OF THE CORE STRUCTURE IN QUINOLONE AND NAPTHYRIDONE CLASS OF ANTIBIOTICS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LA STRUCTURE CENTRALE D'ANTIBIOTIQUES APPARTENANT AUX CLASSES QUINOLONE ET NAPHTHYRIDONE
  申请人：INDIAN INST TECHNOLOGY MADRAS

  公开号：WO2013157018A1

  公开（公告）日：2013-10-24

  This invention relates to quinolone- and naphthyridone derivatives represented by the general formula VII, and a process for their preparation using Baylis-Hillman adducts from substituted aromatic or hetero-aromatic aldehydes and amines of interest as the starting materials. After the tandem Aza-Michael addition and SNAr cyclization, the resulting 4-hydroxy-1,2,3,4-tetrahydroquinoline or 4-hydroxy-1, 2,3,4- tetrahydro-1,8-naphthyridine derivative was subjected to oxidation to get the quinolone or naphthyridone skeleton in one step in good to excellent yields.

  本发明涉及通式VII所代表的喹诺酮和萘啶酮衍生物，以及使用取代芳香族或杂芳香族醛和感兴趣的胺作为起始材料，从Baylis-Hillman加合物开始制备它们的过程。在串联的Aza-Michael加成和SNAr环化之后，所得的4-羟基-1,2,3,4-四氢喹啉或4-羟基-1,2,3,4-四氢-1,8-萘啶衍生物被氧化，从而在一步中以良好至优异的收率得到喹诺酮或萘啶酮骨架。